HTBX Corporate Milestones Below we list key milestones for Heat Biologics:
1 - Complete HS-110 Phase II NSCLC enrollment – 2Q:19 2 - HS-130 (ComPACT) IND filing and FDA Clearance – August 2019 3 - HS-110 interim data readout – November 2019 4 - HS-110 Phase II interim readout – 4Q:19 5 - PTX-35 IND clearance and first patient dosing – 2Q:20 6 - Various coronavirus vaccine milestones – 2Q:20 7 - ASCO Poster Presentation – May 29, 2020 8 - Discussion with potential partners – Ongoing 9 - Schedule End of Phase II Meeting with FDA – 2H:20 10 - Complete HS-130 Phase I trial – 4Q:20 11 - Develop Phase III / commercial manufacturing capacity for HS-110 2020